Clinical trial
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal…
NCT00125034 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00125034 |
|---|---|
| Title | Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) |
| Official title | Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer |
| Acronym | OPUS |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasm Metastasis, Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | Cetuximab, Oxaliplatin |
| Enrollment | 344 |
| Start date | Jul 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Nov 1, 2010 |
| First posted | Jul 29, 2005 |
| Last update posted | Aug 7, 2014 |
| Countries | Austria, Belgium, France, Germany, Greece, Israel, Italy, Poland, Portugal, Romania, Russia, Spain and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: